Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Title
Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Authors
Keywords
-
Journal
CLINICAL CANCER RESEARCH
Volume 24, Issue 12, Pages 2771-2779
Publisher
American Association for Cancer Research (AACR)
Online
2018-03-21
DOI
10.1158/1078-0432.ccr-17-2398

Ask authors/readers for more resources

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search